Neuroscience Antibodies and Assays Market Overview
As per Econ Market Research analysis, the Global Neuroscience Antibodies and Assays Market was recorded at US$ 4.1 Billion in 2026 and is projected to expand to US$ 6.3 Billion by 2035, registering a CAGR of 4.88% over the forecast period. The base year used is 2025.
Neuroscience assays and antibodies are essential tools for studying the nervous system because they allow scientists to look into many facets of brain anatomy, function, and disorders. These specialised proteins, known as antibodies, are made to attach to particular sites in the nervous system in order to help locate and identify important molecules that are involved in neuronal functions. Conversely, assays are experimental processes that use these antibodies to identify and measure particular biomolecules, offering important insights into the complex workings of the brain.
As scientists and pharmaceutical companies step up their efforts to comprehend and create treatments for neurological disorders like Parkinson',s disease, Alzheimer',s disease, and various psychiatric conditions, the market is characterised by a growing demand for advanced neuroscience tools. This market is growing as a result of factors like increased funding for neuroscience research, rising prevalence of neurological disorders, and technological advancements. The industry',s overall growth is facilitated by the development of high-quality and innovative antibodies and assays, which are essential for accurate and dependable neuroscience research.
Neuroscience Antibodies and Assays Dynamics
One major factor is the increasing global prevalence of neurological disorders, which calls for intensive research and development to find new treatments. By improving the accuracy and productivity of neuroscience research, technological developments in antibody production and assay techniques&mdash,including the introduction of sophisticated imaging modalities and high-throughput screening methods&mdash,are driving the market.
The industry is distinguished by a steady stream of capital and funding going towards neuroscience research, which encourages creativity and the creation of innovative instruments. Collaborations among academic institutions, pharmaceutical companies, and Biotechnology firms are on the rise, creating synergistic effects that boost market expansion and accelerate product development. Additionally, the need for specialised antibodies and assays is being driven by the growing knowledge of the cellular and molecular details of neurological disorders, which is building a strong market ecosystem.
Neuroscience Antibodies and Assays Drivers
Increasing Prevalence of Neurological Disorders
Growing rates of neurological diseases, such as Parkinson',s disease, Alzheimer',s disease, and other psychiatric disorders, are a major factor propelling the global market for neuroscience antibodies and assays. The prevalence of these disorders keeps rising as the world',s population ages and lifestyles change, requiring significant research and development efforts. In order to facilitate the development of targeted therapeutics, it is imperative to comprehend the underlying molecular and cellular mechanisms of these disorders, which in turn drives the demand for advanced neuroscience tools like antibodies and assays.
Technological Advancements in Neuroscience Research
The market is driven forward by the rapid technological advancements in neuroscience research, especially in the fields of imaging techniques and high-throughput screening methods. The incorporation of state-of-the-art technologies augments the accuracy and efficacy of neuroscience investigations, permitting scholars to investigate the intricacies of the nervous system with unparalleled minutiae. Our understanding of brain function and pathology is advanced by the development of novel tools and techniques that enable more accurate biomolecule detection and quantification. The capabilities of neuroscience research are increased by this technological advancement, which also increases demand for complex antibodies and assays and propels market expansion.
Restraints:
Complexity of Neurological Research
The market is severely constrained by the complex nature of neurological research. Deciphering intricate interactions between different molecules and pathways is a challenge when studying the nervous system, making it difficult to pinpoint precise targets for antibodies. Neurological disorders are complex due to their multifaceted nature, necessitating careful experimental design and interpretation. It can take a lot of time and resources to develop highly specific and dependable antibodies and assays, but these problems require constant innovation.
Regulatory Challenges and Ethical Considerations
Stringent regulatory requirements and ethical considerations surrounding antibody development and assay techniques present restraints to market growth. Adhering to regulatory frameworks for product approval is essential but can be a time-consuming process. Additionally, ethical concerns related to the use of animals in antibody development may lead to increased scrutiny and necessitate the exploration of alternative methods. Navigating these regulatory and ethical challenges requires significant investments in research and development, potentially impacting the speed of product commercialization.
Opportunities:
Growing Collaborations in Research and Development
Opportunities abound in the increasing trend of collaborations between academic institutions, pharmaceutical companies, and biotechnology firms. Partnerships foster synergies, combining diverse expertise and resources to accelerate product development and innovation. Collaborative efforts can lead to the creation of novel antibodies and assays, tapping into a broader knowledge base and potentially unlocking new avenues for neuroscience research and therapeutic interventions.
Segment Overview
By Product Type
The market is segmented into consumables and instruments. Consumables encompass a range of products essential for neuroscience research, including antibodies, assay kits, reagents, and other laboratory supplies. These are the recurring and often disposable components required for experiments and analyses. Instruments, on the other hand, comprise the equipment and machinery utilized in neuroscience laboratories, such as imaging systems, analyzers, and other advanced tools. Both consumables and instruments play integral roles in facilitating accurate and efficient neuroscience research, with advancements in technology driving the development of innovative products in each category.
By Technology
The technology segment encompasses immunoassays/immunochemistry, molecular diagnostics, and other technologies. Immunoassays and immunochemistry involve the use of antibodies to detect and quantify specific molecules, offering high specificity and sensitivity in neuroscience research. Molecular diagnostics focus on the genetic and molecular aspects of neurological disorders, providing insights into the underlying molecular mechanisms. Other technologies may include emerging approaches and tools that contribute to the diverse toolkit available to researchers. The dynamic interplay between these technologies reflects the multifaceted nature of neuroscience research, allowing for a comprehensive exploration of the nervous system',s intricacies.
By End User
The end user segment includes academic and research institutes, pharmaceutical and biotechnology companies, and other end users. Academic and research institutes form the backbone of neuroscience research, driving scientific discovery and knowledge generation. Pharmaceutical and biotechnology companies leverage neuroscience tools in drug discovery and development processes, aiming to bring novel therapies to market. Other end users may include diagnostic laboratories, healthcare institutions, and contract research organizations, representing a diverse array of entities contributing to and benefiting from advancements in neuroscience antibodies and assays. The collaboration and interaction among these end users foster a dynamic ecosystem that accelerates innovation and addresses the complex challenges associated with neurological research and therapeutic development.
Neuroscience Antibodies and Assays Overview by Region
Due to its strong presence of top biotechnology and pharmaceutical companies, reputable academic and research institutions, and large investments in neuroscience research, North America currently commands the largest share of the market. The area has favourable regulatory frameworks and a developed healthcare ecosystem, which promote the creation and uptake of cutting-edge neuroscience tools.
Europe is closely behind, with a focus on academic research, especially in nations with well-known neuroscience research centres. Collaborative initiatives between academia and industry drive innovation and facilitate the translation of research findings into clinical applications, which benefits the European market. Furthermore, bolstering government funding for neuroscience research is a factor in the region',s expansion.
Asia-Pacific represents a rapidly expanding market, propelled by a rising focus on scientific research, a growing pool of skilled researchers, and increasing investments in healthcare infrastructure. Countries like China, Japan, and India are at the forefront of neuroscience research initiatives, with a burgeoning demand for advanced antibodies and assays. The Asia-Pacific market also benefits from collaborations with international research organizations and the globalization of pharmaceutical and biotechnology industries.
Neuroscience Antibodies and Assays Market Competitive Landscape
Leading pharmaceutical and biotechnology companies, such as Thermo Fisher Scientific, Merck Group, and Abcam plc, dominate the market with their extensive product portfolios, robust research and development capabilities, and global market presence. These companies invest significantly in the development of cutting-edge antibodies and assay technologies, ensuring a continuous stream of advanced solutions to meet the evolving needs of neuroscience researchers.
In addition to industry giants, a vibrant ecosystem of niche players and emerging start-ups contributes to the competitive dynamics. These entities focus on niche markets, offering specialized antibodies and assays that cater to specific research requirements. This diverse landscape fosters innovation and provides researchers with a broad spectrum of tools for their studies. Strategic collaborations between industry players and academic institutions further amplify the competitive intensity, promoting knowledge exchange and the development of novel solutions.
The market also witnesses mergers and acquisitions as key players seek to expand their product portfolios and enhance their market share. Partnerships between technology providers and research institutions facilitate the integration of cutting-edge technologies into neuroscience research, fuelling market growth. As the demand for personalized medicine grows, companies are increasingly investing in technologies that enable the customization of antibodies and assays for specific patient profiles, presenting a new frontier in the competitive landscape.
Neuroscience Antibodies and Assays Market Leading Companies:
Abcam plc
BioLegend Inc.
Bio-Rad Laboratories Inc.
Cell Signaling Technology Inc.
F. Hoffmann-La Roche AG
Thermo Fisher Scientific
Merck KGaA
Rockland Immunochemicals Inc.
GenScript Biotech Corporation
Santa Cruz Biotechnology Inc.
Global Neuroscience Antibodies and Assays Report Segmentation
Neuroscience Antibodies and Assays Market Segmentation
| Segment Category | Segment Values |
|---|---|
| Product |
|
| Technology |
|
| End-User |
|
Key Players
- Thermo Fisher
- Bio-Rad
- Merck KGaA
- Abcam
- Cell Signaling Technology
- Bio-Techne
- Genscript
- Rockland Immunochemicals
Table of Contents
1. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET–REPORT OVERVIEW
- 1.1. SCOPE OF THE REPORT
- 1.2. MARKET SEGMENT ANALYSIS
- 1.3. REGULATORY SCENARIO BY REGION/COUNTRY
- 1.4. MARKET INVESTMENT SCENARIO STRATEGIC
- 1.5. MARKET ANALYSIS BY BY PRODUCT (USD MILLION)
- 1.5.1 GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE BY BY PRODUCT (2026-2035)
- 1.5.2 CONSUMABLES
- 1.5.3 INSTRUMENTS
- 1.6. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE BY BY PRODUCT IN 2026 & 2035
- 1.7. MARKET ANALYSIS BY BY TECHNOLOGY (USD MILLION)
- 1.7.1 GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE BY BY TECHNOLOGY (2026-2035)
- 1.7.2 IMMUNOASSAYS/IMMUNOCHEMISTRY
- 1.7.3 MOLECULAR DIAGNOSTICS
- 1.7.4 OTHERS
- 1.8. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE BY BY TECHNOLOGY IN 2026 & 2035
- 1.9. MARKET ANALYSIS BY BY END-USER (USD MILLION)
- 1.9.1 GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE BY BY END-USER (2026-2035)
- 1.9.2 ACADEMIC ANDAMP; RESEARCH INSTITUTES
- 1.9.3 PHARMACEUTICAL ANDAMP; BIOTECHNOLOGY COMPANIES
- 1.9.4 OTHERS
- 1.10. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE BY BY END-USER IN 2026 & 2035
2. DRIVER RESTRAINT CHALLENGE AND OPPORTUNITIES OF NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET
- 2.1. DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
- 2.1.1 MARKET DRIVER ANALYSIS
- 2.1.2 MARKET RESTRAINT ANALYSIS
- 2.1.3 MARKET OPPORTUNITY
- 2.2. MARKET CHALLENGES
3. GLOBAL GROWTH TRENDS
- 3.1. INDUSTRY TRENDS
- 3.1.1 SWOT ANALYSIS
- 3.1.1.1 Strengths
- 3.1.1.2 Weaknesses
- 3.1.1.3 Opportunities
- 3.1.1.4 Threats
- 3.1.2 PESTEL ANALYSIS
- 3.1.2.1 Political Landscape
- 3.1.2.2 Economic Landscape
- 3.1.2.3 Social Landscape
- 3.1.2.4 Technological Landscape
- 3.1.2.5 Environmental Landscape
- 3.1.2.6 Legal Landscape
- 3.1.3 PORTER'S FIVE FORCES ANALYSIS
- 3.1.3.1 Bargaining Power of Suppliers
- 3.1.3.2 Bargaining Power of Buyers
- 3.1.3.3 Threat of Substitute
- 3.1.3.4 Threat of New Entrant
- 3.1.3.5 Competitive Rivalry
- 3.1.1 SWOT ANALYSIS
- 3.2. POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4. POST COVID ANALYSIS
- 4.1. COVID V ANALYSIS
- 4.2. COVID U ANALYSIS
- 4.3. COVID L ANALYSIS
- 4.4. COVID W ANALYSIS
5. COMPANIES ANALYSIS
- 5.1. PLAYERS COVERED: RANKING BY NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET REVENUE
- 5.2. TOP COMPANIES MARKET SHARE (%)
6. EXECUTIVE SUMMARY
7. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET FORECAST, 2022-2035, (USD MILLION)
- 7.1. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET REVENUE AND MARKET SHARE BY REGIONS
- 7.2. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY REGION (2022-2029)
- 7.3. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY REGION (2030-2035)
- 7.3.1.1 North America
- 7.3.1.2 Europe
- 7.3.1.3 Asia Pacific
- 7.3.1.4 Latin America
- 7.3.1.5 Middle East & Africa
8. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 8.1. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 8.2. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 8.3. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 8.3.1.1 United States
- 8.3.1.2 Canada
- 8.3.1.3 Mexico
9. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 9.1. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 9.2. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 9.3. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 9.3.1.1 United Kingdom
- 9.3.1.2 Germany
- 9.3.1.3 France
- 9.3.1.4 Spain
- 9.3.1.5 Italy
- 9.3.1.6 Rest of Europe
10. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 10.1. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 10.2. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 10.3. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 10.3.1.1 China
- 10.3.1.2 India
- 10.3.1.3 Japan
- 10.3.1.4 Australia
- 10.3.1.5 South Korea
- 10.3.1.6 Rest of Asia Pacific
11. MIDDLE EAST AND AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 11.1. MIDDLE EAST AND AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 11.2. MIDDLE EAST & AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 11.3. MIDDLE EAST & AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 11.3.1.1 Saudi Arabia
- 11.3.1.2 South Africa
- 11.3.1.3 Rest of MEA
12. LATIN AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET ANALYSIS BY COUNTRIES, (USD MILLION)
- 12.1. LATIN AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET REVENUE AND MARKET SHARE BY COUNTRIES
- 12.2. LATIN AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY COUNTRY (2022-2029)
- 12.3. LATIN AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY COUNTRY (2030-2035)
- 12.3.1.1 Brazil
- 12.3.1.2 Argentina
- 12.3.1.3 Rest of Latin America
13. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SEGMENT BY BY PRODUCT, (USD MILLION)
- 13.1. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY PRODUCT (2022-2029)
- 13.2. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY PRODUCT (2030-2035)
- 13.3. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY PRODUCT (2022-2029)
- 13.4. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY PRODUCT (2030-2035)
- 13.5. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY PRODUCT (2022-2029)
- 13.6. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY PRODUCT (2030-2035)
- 13.7. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY PRODUCT (2022-2029)
- 13.8. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY PRODUCT (2030-2035)
- 13.9. MIDDLE EAST & AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY PRODUCT (2022-2029)
- 13.10. MIDDLE EAST & AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY PRODUCT (2030-2035)
- 13.11. SOUTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY PRODUCT (2022-2029)
- 13.12. SOUTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY PRODUCT (2030-2035)
13. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SEGMENT BY BY TECHNOLOGY, (USD MILLION)
- 13.13. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY TECHNOLOGY (2022-2029)
- 13.14. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY TECHNOLOGY (2030-2035)
- 13.15. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY TECHNOLOGY (2022-2029)
- 13.16. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY TECHNOLOGY (2030-2035)
- 13.17. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY TECHNOLOGY (2022-2029)
- 13.18. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY TECHNOLOGY (2030-2035)
- 13.19. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY TECHNOLOGY (2022-2029)
- 13.20. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY TECHNOLOGY (2030-2035)
- 13.21. MIDDLE EAST & AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY TECHNOLOGY (2022-2029)
- 13.22. MIDDLE EAST & AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY TECHNOLOGY (2030-2035)
- 13.23. SOUTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY TECHNOLOGY (2022-2029)
- 13.24. SOUTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY TECHNOLOGY (2030-2035)
13. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SEGMENT BY BY END-USER, (USD MILLION)
- 13.25. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY END-USER (2022-2029)
- 13.26. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY END-USER (2030-2035)
- 13.27. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY END-USER (2022-2029)
- 13.28. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY END-USER (2030-2035)
- 13.29. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY END-USER (2022-2029)
- 13.30. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY END-USER (2030-2035)
- 13.31. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY END-USER (2022-2029)
- 13.32. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY END-USER (2030-2035)
- 13.33. MIDDLE EAST & AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY END-USER (2022-2029)
- 13.34. MIDDLE EAST & AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY END-USER (2030-2035)
- 13.35. SOUTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY END-USER (2022-2029)
- 13.36. SOUTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET AND MARKET SHARE BY BY END-USER (2030-2035)
14. COMPANY PROFILES
- 14.1. THERMO FISHER
- 14.1.1 COMPANY DETAIL
- 14.1.2 FINANCIALS (USD MILLIONS)
- 14.1.3 PRODUCT SUMMARY
- 14.1.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.2. BIO-RAD
- 14.2.1 COMPANY DETAIL
- 14.2.2 FINANCIALS (USD MILLIONS)
- 14.2.3 PRODUCT SUMMARY
- 14.2.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.3. MERCK KGAA
- 14.3.1 COMPANY DETAIL
- 14.3.2 FINANCIALS (USD MILLIONS)
- 14.3.3 PRODUCT SUMMARY
- 14.3.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.4. ABCAM
- 14.4.1 COMPANY DETAIL
- 14.4.2 FINANCIALS (USD MILLIONS)
- 14.4.3 PRODUCT SUMMARY
- 14.4.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.5. CELL SIGNALING TECHNOLOGY
- 14.5.1 COMPANY DETAIL
- 14.5.2 FINANCIALS (USD MILLIONS)
- 14.5.3 PRODUCT SUMMARY
- 14.5.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.6. BIO-TECHNE
- 14.6.1 COMPANY DETAIL
- 14.6.2 FINANCIALS (USD MILLIONS)
- 14.6.3 PRODUCT SUMMARY
- 14.6.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.7. GENSCRIPT
- 14.7.1 COMPANY DETAIL
- 14.7.2 FINANCIALS (USD MILLIONS)
- 14.7.3 PRODUCT SUMMARY
- 14.7.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
- 14.8. ROCKLAND IMMUNOCHEMICALS
- 14.8.1 COMPANY DETAIL
- 14.8.2 FINANCIALS (USD MILLIONS)
- 14.8.3 PRODUCT SUMMARY
- 14.8.4 RECENT DEVELOPMENTS (MERGERS, ACQUISITION, LAUNCH & OTHERS)
15. CONCLUSION
16. REFERENCE LINK
17. APPENDIX
- 17.1. METHODOLOGY
- 17.2. RESEARCH DATA SOURCE
- 17.2.1 SECONDARY DATA
- 17.2.2 KEY DATA FROM SECONDARY
- 17.2.3 PRIMARY DATA
- 17.2.4 KEY DATA FROM PRIMARY
- 17.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
- 17.2.6 MARKET ESTIMATION
- 17.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
- 17.2.8 LEGAL DISCLAIMER
18. RESEARCH SCOPE
LIST OF TABLES
- TABLE 1. MARKET SEGMENT
- TABLE 2. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET GROWTH RATE BY BY PRODUCT (2026-2035)
- TABLE 3. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET GROWTH RATE BY BY TECHNOLOGY (2026-2035)
- TABLE 4. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET GROWTH RATE BY BY END-USER (2026-2035)
- TABLE 5. COMPANY'S RANK BY NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET REVENUE
- TABLE 6. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET — MARKET SNAPSHOT & KEY BUYING CRITERIA, 2026–2035
- TABLE 7. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 8. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 9. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY REGION, USD MILLION (2022-2029)
- TABLE 10. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE BY REGION, (2022-2029)
- TABLE 11. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY REGION, USD MILLION (2030-2035)
- TABLE 12. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE BY REGION, (2030-2035)
- TABLE 13. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 14. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 15. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 16. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 17. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 18. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 19. MIDDLE EAST AND AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 20. MIDDLE EAST AND AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 21. LATIN AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 22. LATIN AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 23. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY COUNTRY, (2022-2029)
- TABLE 24. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 25. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY COUNTRY, (2030-2035)
- TABLE 26. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 27. UNITED STATES NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 28. UNITED STATES NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 29. CANADA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 30. CANADA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 31. MEXICO NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 32. MEXICO NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 33. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY COUNTRY, (2022-2029)
- TABLE 34. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 35. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY COUNTRY, (2030-2035)
- TABLE 36. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 37. UNITED KINGDOM NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 38. UNITED KINGDOM NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 39. GERMANY NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 40. GERMANY NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 41. FRANCE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 42. FRANCE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 43. SPAIN NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 44. SPAIN NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 45. ITALY NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 46. ITALY NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 47. REST OF EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 48. REST OF EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 49. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY COUNTRY, (2022-2029)
- TABLE 50. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 51. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY COUNTRY, (2030-2035)
- TABLE 52. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 53. CHINA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 54. CHINA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 55. INDIA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 56. INDIA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 57. JAPAN NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 58. JAPAN NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 59. AUSTRALIA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 60. AUSTRALIA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 61. SOUTH KOREA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 62. SOUTH KOREA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 63. REST OF ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 64. REST OF ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 65. MIDDLE EAST AND AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY COUNTRY, (2022-2029)
- TABLE 66. MIDDLE EAST AND AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 67. MIDDLE EAST AND AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY COUNTRY, (2030-2035)
- TABLE 68. MIDDLE EAST AND AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 69. SAUDI ARABIA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 70. SAUDI ARABIA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 71. SOUTH AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 72. SOUTH AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 73. REST OF MEA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 74. REST OF MEA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 75. LATIN AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY COUNTRY, (2022-2029)
- TABLE 76. LATIN AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE BY COUNTRY, (2022-2029)
- TABLE 77. LATIN AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY COUNTRY, (2030-2035)
- TABLE 78. LATIN AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE BY COUNTRY, (2030-2035)
- TABLE 79. BRAZIL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 80. BRAZIL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 81. ARGENTINA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 82. ARGENTINA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 83. REST OF LATIN AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2022-2029)
- TABLE 84. REST OF LATIN AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (USD MILLION) (2030-2035)
- TABLE 85. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY PRODUCT, USD MILLION (2022-2029)
- TABLE 86. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY PRODUCT, USD MILLION (2030-2035)
- TABLE 87. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY PRODUCT, USD MILLION (2022-2029)
- TABLE 88. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY PRODUCT, USD MILLION (2030-2035)
- TABLE 89. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY PRODUCT, USD MILLION (2022-2029)
- TABLE 90. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY PRODUCT, USD MILLION (2030-2035)
- TABLE 91. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY PRODUCT, USD MILLION (2022-2029)
- TABLE 92. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY PRODUCT, USD MILLION (2030-2035)
- TABLE 93. MIDDLE EAST & AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY PRODUCT, USD MILLION (2022-2029)
- TABLE 94. MIDDLE EAST & AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY PRODUCT, USD MILLION (2030-2035)
- TABLE 95. SOUTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY PRODUCT, USD MILLION (2022-2029)
- TABLE 96. SOUTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY PRODUCT, USD MILLION (2030-2035)
- TABLE 97. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY TECHNOLOGY, USD MILLION (2022-2029)
- TABLE 98. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY TECHNOLOGY, USD MILLION (2030-2035)
- TABLE 99. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY TECHNOLOGY, USD MILLION (2022-2029)
- TABLE 100. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY TECHNOLOGY, USD MILLION (2030-2035)
- TABLE 101. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY TECHNOLOGY, USD MILLION (2022-2029)
- TABLE 102. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY TECHNOLOGY, USD MILLION (2030-2035)
- TABLE 103. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY TECHNOLOGY, USD MILLION (2022-2029)
- TABLE 104. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY TECHNOLOGY, USD MILLION (2030-2035)
- TABLE 105. MIDDLE EAST & AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY TECHNOLOGY, USD MILLION (2022-2029)
- TABLE 106. MIDDLE EAST & AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY TECHNOLOGY, USD MILLION (2030-2035)
- TABLE 107. SOUTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY TECHNOLOGY, USD MILLION (2022-2029)
- TABLE 108. SOUTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY TECHNOLOGY, USD MILLION (2030-2035)
- TABLE 109. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY END-USER, USD MILLION (2022-2029)
- TABLE 110. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY END-USER, USD MILLION (2030-2035)
- TABLE 111. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY END-USER, USD MILLION (2022-2029)
- TABLE 112. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY END-USER, USD MILLION (2030-2035)
- TABLE 113. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY END-USER, USD MILLION (2022-2029)
- TABLE 114. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY END-USER, USD MILLION (2030-2035)
- TABLE 115. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY END-USER, USD MILLION (2022-2029)
- TABLE 116. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY END-USER, USD MILLION (2030-2035)
- TABLE 117. MIDDLE EAST & AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY END-USER, USD MILLION (2022-2029)
- TABLE 118. MIDDLE EAST & AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY END-USER, USD MILLION (2030-2035)
- TABLE 119. SOUTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY END-USER, USD MILLION (2022-2029)
- TABLE 120. SOUTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET BY BY END-USER, USD MILLION (2030-2035)
LIST OF FIGURES
- FIGURE 1. MARKET OVERVIEW
- FIGURE 2. REGIONAL SHARE
- FIGURE 3. MARKET REVENUE (USD MILLION)
- FIGURE 4. DROC OF NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET ANALYSIS
- FIGURE 5. SWOT ANALYSIS
- FIGURE 6. PESTEL ANALYSIS
- FIGURE 7. PORTER'S FIVE FORCES ANALYSIS
- FIGURE 8. COVID V, U, W AND L ANALYSIS
- FIGURE 9. LEADING COMPANIES
- FIGURE 10. REGIONAL ANALYSIS
- FIGURE 11. COUNTRY ANALYSIS
- FIGURE 12. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 13. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 14. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION), BY REGION
- FIGURE 15. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE, (2026), BY REGION
- FIGURE 16. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION), BY REGION
- FIGURE 17. GLOBAL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE, (2035), BY REGION
- FIGURE 18. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 19. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 20. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 21. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 22. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 23. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 24. MIDDLE EAST AND AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 25. MIDDLE EAST AND AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 26. LATIN AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 27. LATIN AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 28. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 29. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE, (2026), BY COUNTRY
- FIGURE 30. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 31. NORTH AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE, (2035), BY COUNTRY
- FIGURE 32. UNITED STATES NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 33. UNITED STATES NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 34. CANADA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 35. CANADA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 36. MEXICO NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 37. MEXICO NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 38. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 39. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE, (2026), BY COUNTRY
- FIGURE 40. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 41. EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE, (2035), BY COUNTRY
- FIGURE 42. UNITED KINGDOM NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 43. UNITED KINGDOM NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 44. GERMANY NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 45. GERMANY NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 46. FRANCE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 47. FRANCE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 48. SPAIN NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 49. SPAIN NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 50. ITALY NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 51. ITALY NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 52. REST OF EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 53. REST OF EUROPE NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 54. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 55. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE, (2026), BY COUNTRY
- FIGURE 56. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 57. ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE, (2035), BY COUNTRY
- FIGURE 58. CHINA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 59. CHINA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 60. INDIA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 61. INDIA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 62. JAPAN NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 63. JAPAN NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 64. AUSTRALIA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 65. AUSTRALIA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 66. SOUTH KOREA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 67. SOUTH KOREA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 68. REST OF ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 69. REST OF ASIA PACIFIC NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 70. MIDDLE EAST AND AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 71. MIDDLE EAST AND AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE, (2026), BY COUNTRY
- FIGURE 72. MIDDLE EAST AND AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 73. MIDDLE EAST AND AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE, (2035), BY COUNTRY
- FIGURE 74. SAUDI ARABIA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 75. SAUDI ARABIA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 76. SOUTH AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 77. SOUTH AFRICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 78. REST OF MEA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 79. REST OF MEA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 80. LATIN AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION), BY COUNTRY
- FIGURE 81. LATIN AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE, (2026), BY COUNTRY
- FIGURE 82. LATIN AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION), BY COUNTRY
- FIGURE 83. LATIN AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET SHARE, (2035), BY COUNTRY
- FIGURE 84. BRAZIL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 85. BRAZIL NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 86. ARGENTINA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 87. ARGENTINA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
- FIGURE 88. REST OF LATIN AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2022-2029), (USD MILLION)
- FIGURE 89. REST OF LATIN AMERICA NEUROSCIENCE ANTIBODIES AND ASSAYS MARKET, (2030-2035), (USD MILLION)
Research Methodology
Our research methodology is carefully designed to deliver the clients with the most accurate, relevant, and actionable market insights to enable clear decision-making and leveraging of opportunities in the markets. We believe consistency, depth in analysis, and a tailored approach in each report are what help set us apart in the industry. The research methodology is based on an integrating research process consisting of in-depth data collection, a complex analysis, and a stringent validation system.
Data Collection
Data collection forms the basis of our study and gathers diverse authentic data to build the basis for deeper study in terms of market trends, competitive landscape, and growth prospects. Data collection takes place through two channels of main activities as follows:
Primary Data Collection
Primary data collection allows collecting real-time and firsthand information from market participants. This is an engagement process conducted by our team with other industry stakeholders, where a much deeper insight than any published data is pursued. This process includes:
- Direct Interviews – We interview the key decision-makers such as CEOs, product managers, innovation heads, and marketing directors to gather both qualitative and quantitative information. The questionnaire covers emerging trends, customer preferences, regulatory impact, and competitors’ strategies.
- Demand and Supply-Side Inputs – Interviews and surveys with supply and demand-side stakeholders provide a balanced view of prevailing market conditions, including feedback from manufacturers, distributors, suppliers, and end-users.
- Expert Opinions – Consultations with industry experts and domain specialists provide insights into future market direction, risks, and opportunities.
- Focus Groups and Online Surveys – Focus groups and surveys are used to understand consumer preferences and adoption probability of new products or services.
Primary research forms the core of our data validation process by offering direct insights into the market, addressing limitations in secondary data, and allowing for an adaptable research process.
Secondary Data Collection
Secondary research serves as a robust foundation for understanding market context, historical data, and larger trends. It involves systematic gathering of existing information from verified sources.
- Industry Reports and Publications – Market reports, white papers, and case studies from credible sources provide a broad view of the market landscape and key players.
- Government and Public Records – Data from government agencies and regulatory bodies helps analyze economic factors and policy impacts.
- News and Media Outlets – Monitoring news articles, press releases, and media reports keeps us updated on market developments and M&A activity.
- Proprietary and Paid Databases – Databases such as Bloomberg, Factiva, D&B Hoovers, and Thomson Reuters provide validated and cross-referenced data.
- Financial Reports and SEC Filings – Financial statements, annual reports, and investor presentations provide insights into revenue structures and profitability.
This combination of primary and secondary data sources enables us to provide a comprehensive view of the market, supported by authenticated information across multiple sources.
Data Analysis Techniques
With the data collected, we initiate a rigorous analysis phase. We analyze market dynamics, growth patterns, and future performance using analytical models and statistical tools.
Top-Down and Bottom-Up Market Sizing Approaches
- Top-Down Approach – Starts with global market size and distributes it across segments using macro-level trends and established proportions.
- Bottom-Up Approach – Aggregates company-level and country-level revenue data to build regional and global market estimates.
These two approaches are cross-validated to remove inconsistencies and ensure accurate market estimation.
Forecasting Models and Market Dynamics Analysis
- Time-Series Analysis – Models historical trends, seasonality, and demand cycles.
- Econometric and Judgmental Forecasting – Combines economic models with expert-driven adjustments.
- Delphi Method – Uses iterative expert input to generate balanced market forecasts.
Data Triangulation and Validation
- Multi-source cross-verification of all data points
- Use of quantitative and qualitative validation techniques
- Sample validation through expert and stakeholder feedback
Market Analysis and Sizing Estimation
- Detailed segmentation analysis
- Competitive landscape evaluation
- Revenue modeling using TAM, SAM, and SOM frameworks
Quality Assurance and Final Review
- Data accuracy and consistency checks
- Content, language, and structure review
- Client-specific customization and refinement
Continuous Improvement in Methodology
We continuously refine our research methodologies based on evolving market conditions, client feedback, and technological advancements. This ensures our research remains accurate, relevant, and aligned with industry standards.
Neuroscience Antibodies and Assays Market Report Scope & Segmentation
| Attributes | Details |
|---|---|
| Market Size (Current)Current market valuation | US$ 4.1 Billion in 2026 |
| Market Size (Forecast)Projected market valuation | US$ 6.3 Billion in 2035 |
| Growth RateCompound Annual Growth Rate | CAGR of 4.88% from 2026 to 2035 |
| Forecast PeriodAnalysis timeline | 2026 – 2035 |
| Base YearReference year for analysis | 2025 |
| Historical Data AvailablePast market data availability | Yes |
| Regional ScopeGeographical coverage | Global |
| Segments CoveredMarket segments analyzed | By Product
By Technology
By End-User
|
Leading companies covered in this report
- Thermo Fisher
- Bio-Rad
- Merck KGaA
- Abcam
- Cell Signaling Technology
- Bio-Techne
- Genscript
- Rockland Immunochemicals
Frequently Asked Questions
Common questions about this report
The study period covers historical insights and forecast projections for the period 2026-2035.
The global Neuroscience Antibodies and Assays Market market is expected to grow at a CAGR of 4.88% during the forecast period 2026-2035.
The report offers comprehensive market segmentation analysis across key categories and sub-segments relevant to the industry, along with regional and competitive insights.
The market is projected to reach 6.3 Billion by 2035.
Key players in the Neuroscience Antibodies and Assays Market include Thermo Fisher, Bio-Rad, Merck KGaA, Abcam, Cell Signaling Technology, Bio-Techne, Genscript, and Rockland Immunochemicals.
North America, Europe, and Asia Pacific are key regions covered in the report, including regional trends, market share, and growth opportunities.
Growing demand, technological advancements, changing consumer preferences, and increasing investments are some of the major factors supporting the growth of the Neuroscience Antibodies and Assays Market market.
Yes, the report includes company profiling, competitive landscape analysis, strategic developments, mergers & acquisitions, product launches, and market positioning of leading industry participants.
The report is prepared using a combination of primary research, secondary research, expert interviews, industry databases, company annual reports, and proprietary market analysis models.
Yes, report customization options are available based on specific business objectives, geographic focus, competitive benchmarking requirements, and additional market segmentation needs.
Yes, the report is available in both PDF and Excel formats. The Excel file includes all market data tables, forecasts, and segment-wise data for easy analysis.
Yes, you can request a free sample report which includes an overview, table of contents, and sample data pages to help you evaluate the report before making a purchase decision.
About the Author
Market research expert with years of industry experience

Dipali Bhingare serves as the Market Research Director at Econ Market Research. With a focus on translating complex global economic shifts into actionable business intelligence, she oversees the strategic direction of comprehensive market studies. Her work empowers organizations to navigate volatile industries through data-driven forecasting and deep-dive competitive analysis.










